Eupraxia Pharmaceuticals Inc. (OTCMKTS:EPRXF – Get Free Report)’s share price shot up 7% on Monday . The stock traded as high as C$6.63 and last traded at C$6.59. Approximately 118,394 shares changed hands during trading, an increase of 1,498% from the average daily volume of 7,410 shares. The stock had previously closed at C$6.16.
Eupraxia Pharmaceuticals Stock Up 7.0%
The firm has a 50 day moving average price of C$6.68 and a 200 day moving average price of C$7.40.
Eupraxia Pharmaceuticals Company Profile
Eupraxia Pharmaceuticals, Inc (OTCMKTS:EPRXF) is a clinical-stage biotechnology company advancing adeno-associated virus (AAV)-based gene therapies for rare inherited metabolic disorders. The firm’s research platform focuses on developing single-administration treatments designed to address the underlying genetic causes of enzyme deficiencies. Eupraxia’s approach leverages targeted gene delivery to restore or supplement critical metabolic functions in patients with life-threatening conditions.
The company’s lead pipeline candidates include EPRX-101 for Ornithine Transcarbamylase (OTC) deficiency and EPRX-102 for methylmalonic acidemia (MMA), both of which are in preclinical or IND-enabling stages.
See Also
- Five stocks we like better than Eupraxia Pharmaceuticals
- The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence
- Is Domino’s Stock Serving Up a Buying Opportunity?
- A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free
- Why Gold Miners Could Be the Market’s Biggest Comeback Story
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
